ALVRQ yields 2000000.00% · JNJ yields 2.13%● Live data
📍 ALVRQ pulled ahead of the other in Year 1
Combined, ALVRQ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ALVRQ + JNJ for your $10,000?
Alvarion Ltd. provides autonomous Wi-Fi network products worldwide. The company designs solutions for carrier Wi-Fi, enterprise connectivity, smart city, smart hospitality, and connected campuses and events. It offers BreezeACCESS, a wireless broadband access solution for license-exempt frequencies; BreezeMAX Extreme, a WiMAX 16e wireless broadband technology; BreezeNET, a point-to-point and point-to-multipoint networking solution for connecting buildings, campuses, industrial zones, and remote sites; and BreezeULTRA, a family of wireless broadband products that operate in the 4.95.9 GHz unlicensed frequency band. The company also provides WBS and WBSn, which are carrier-grade outdoor Wi-Fi base stations; WBSac, a carrier-grade Wi-Fi solution for buildings, workplaces, universities, schools, hospitals, hotels, and large stores; Arena Controller, a Wi-Fi cloud controller that acts as mediation device between the operator's control core and the Wi-Fi infrastructure; and Star Management Suite, a set of carrier-class tools, which support the wireless broadband life-cycle - from initial installation to full service provision, and ongoing maintenance and support activities. It serves carriers, local governments, and hospitality sectors. The company was formerly known as BreezeCOM Ltd. and changed its name to Alvarion Ltd. as result of merger with Floware Wireless Systems Ltd. in August 2001. The company was founded in 1992 and is headquartered in Herzliya, Israel. Alvarion Ltd. is a subsidiary of SuperCom Ltd.
Full ALVRQ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.